3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
2
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
13
Cyclophosphamide
9
Magnetic Resonance Spectroscopy
7
Lenalidomide
7
venetoclax
6
obinutuzumab
5
ibrutinib
5
Specimen Handling
5
fludarabine phosphate
4
fludarabine
4
Whole-Body Irradiation
4
Prednisone
4
CT-P10
4
Biopsy
4
zanubrutinib
3
orelabrutinib
3
Vincristine
3
Mycophenolic Acid
3
Cyclosporine
3
polatuzumab vedotin
2
pirtobrutinib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Busulfan
2
Bendamustine Hydrochloride
2
voruciclib
1
treosulfan
1
tafasitamab
1
prednylidene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
Maintenance
×
90 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled